ABIONYX Pharma Crecimiento futuro
Future controles de criterios 2/6
ABIONYX Pharma's earnings are forecast to decline at 23.4% per annum while its annual revenue is expected to grow at 40.7% per year. EPS is expected to decline by 13.8% per annum.
Información clave
-23.4%
Tasa de crecimiento de los beneficios
-13.8%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 8.4% |
Tasa de crecimiento de los ingresos | 40.7% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 22 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 12 | -7 | -7 | -7 | 1 |
12/31/2025 | 7 | -9 | -9 | -9 | 1 |
12/31/2024 | 5 | -6 | -6 | -6 | 1 |
6/30/2024 | 5 | -3 | -3 | -3 | N/A |
3/31/2024 | 5 | -3 | -3 | -3 | N/A |
12/31/2023 | 5 | -4 | -4 | -4 | N/A |
9/30/2023 | 5 | -4 | N/A | N/A | N/A |
6/30/2023 | 5 | -4 | -2 | -2 | N/A |
3/31/2023 | 5 | -4 | -3 | -3 | N/A |
12/31/2022 | 5 | -4 | -4 | -3 | N/A |
9/30/2022 | 4 | -5 | N/A | N/A | N/A |
6/30/2022 | 3 | -6 | -6 | -6 | N/A |
3/31/2022 | 2 | -6 | -6 | -6 | N/A |
12/31/2021 | 1 | -6 | -7 | -7 | N/A |
9/30/2021 | 0 | -5 | N/A | N/A | N/A |
6/30/2021 | 0 | -4 | -6 | -5 | N/A |
3/31/2021 | 0 | -3 | -3 | -3 | N/A |
12/31/2020 | N/A | -2 | -1 | -1 | N/A |
9/30/2020 | N/A | -2 | -1 | -1 | N/A |
6/30/2020 | N/A | -2 | 0 | 0 | N/A |
3/31/2020 | N/A | 0 | -2 | -2 | N/A |
12/31/2019 | N/A | 2 | -4 | -4 | N/A |
9/30/2019 | 0 | 1 | -5 | -5 | N/A |
6/30/2019 | 0 | 0 | -6 | -6 | N/A |
3/31/2019 | 0 | -3 | -6 | -6 | N/A |
12/31/2018 | 0 | -6 | -6 | -6 | N/A |
9/30/2018 | 0 | -7 | -6 | -6 | N/A |
6/30/2018 | N/A | -8 | -7 | -7 | N/A |
3/31/2018 | N/A | -6 | N/A | -8 | N/A |
12/31/2017 | N/A | -5 | N/A | -9 | N/A |
9/30/2017 | N/A | -8 | N/A | -11 | N/A |
6/30/2017 | N/A | -11 | N/A | -13 | N/A |
3/31/2017 | N/A | -18 | N/A | -16 | N/A |
12/31/2016 | N/A | -25 | N/A | -19 | N/A |
9/30/2016 | N/A | -25 | N/A | -19 | N/A |
6/30/2016 | N/A | -24 | N/A | -19 | N/A |
3/31/2016 | N/A | -20 | N/A | -16 | N/A |
12/31/2015 | N/A | -17 | N/A | -14 | N/A |
9/30/2015 | N/A | -13 | N/A | -11 | N/A |
6/30/2015 | N/A | -10 | N/A | -8 | N/A |
3/31/2015 | N/A | -8 | N/A | -6 | N/A |
12/31/2014 | N/A | -7 | N/A | -3 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: ABNX is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: ABNX is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: ABNX is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: ABNX's revenue (40.7% per year) is forecast to grow faster than the French market (5.6% per year).
Ingresos de alto crecimiento: ABNX's revenue (40.7% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if ABNX's Return on Equity is forecast to be high in 3 years time